Product

Selitrectinib

Aliases

Loxo-195, Selitrectinib (BAY2731954)

1 clinical trial

1 indication

Indication

NTRK Fusion Positive Solid Tumors

Clinical trial

A Phase 1 Study of the TRK Inhibitor Selitrectinib (BAY 2731954) in Adult and Pediatric Subjects With Previously Treated NTRK Fusion Cancers

Status: Completed, Estimated PCD: 2022-04-11